SUMMIT European Cannabis Insights Summit 2026 — Exclusive industry intelligence Register Now

EVENT Cannabis Europa London 2026 — Europe's cannabis industry unites Get Tickets

Clinical Study

Evaluation of THC-Related Neuropsychiatric Symptoms Among Adults Aged 50 Years and Older: A Systematic Review and Metaregression Analysis.

Velayudhan L; McGoohan KL; Bhattacharyya S ·JAMA network open ·2021 ·DOI: 10.1001/jamanetworkopen.2020.35913

Abstract

This systematic review and metaregression analysis estimates the association between the delta-9-tetrahydrocannabinol (THC) dose of cannabinoid-based medicines and neuropsychiatric adverse events among adults aged 50 years and older.

Methodology

TypeMeta-Analysis

Citation

View on PubMed

Evidence Strength

Moderate evidence 68 / 100

Methodology 25/25

Highest-tier methodology assigned to the study.

Sample size 0/25

Sample size not recorded.

Peer review 25/25

Published in a peer-reviewed, PubMed-indexed journal.

Replication / recency 18/25

Published in the last 5 years; replication evidence pending.

How is this calculated?

Other studies in this cluster

Neurology

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2017

RCT n=30

Neurology

Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2015

Neurology

Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.

Journal of clinical pharmacology · 2015

Neurology

Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.

Pain medicine (Malden, Mass.) · 2016

RCT

Neurology

A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.

Expert review of pharmacoeconomics & outcomes research · 2016

Neurology

Health Authorities Data Collection of THC:CBD Oromucosal Spray (L’Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.

European neurology · 2016

Evaluation of THC-Related Neuropsychiatric Symptoms Among Adults Aged 50 Years and Older: A Systematic Review and Metaregression Analysis.

Abstract

Methodology

Citation

Other studies in this cluster

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.

Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.

Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.

Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.

A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.

Health Authorities Data Collection of THC:CBD Oromucosal Spray (L’Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.

Contact us

Categories

Editions

Business of cannabis

Popular

Time is running out to nominate

Recent Searches

Popular Searches

Recent Searches

Popular Searches

Evaluation of THC-Related Neuropsychiatric Symptoms Among Adults Aged 50 Years and Older: A Systematic Review and Metaregression Analysis.

Abstract

Methodology

Citation

Other studies in this cluster

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.

Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.

Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.

Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.

A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.

Health Authorities Data Collection of THC:CBD Oromucosal Spray (L’Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.

Cannabis news, every Monday morning.

Time is running out to nominate